Andrew K. Gonsalves, Esq., who serves as the Chair of the Biotech Group at HRFM, moderated a panel at the NewYorkBIO 25th Anniversary Conference in NYC this week, entitled “Strategic IP Management of Biomarker and Diagnostic Technologies.”  The panel focused on the challenges facing the biotech industry and research universities regarding the commercialization of technologies involving biomarkers, molecular diagnostics, and other gene-based inventions.  The panel included Kevin E. Noonan, J.D., Ph.D., partner at McDonnell Boehnen Hulbert & Berghoff LLP, who is a noted biotech patent attorney and co-founder of the well-respected biotech patent law blog, Patent Docs.  Dr. Noonan provided an informative background of the recent case law on patent eligibility as it relates to biotech inventions, including a trio of U.S. Supreme Court cases commonly referred to as Prometheus, Myriad, and Alice.  Three CEOs from a diverse collection of biotech companies provided their perspective on how the changes in patent eligibility rules have affected how they conduct business.  These CEOs included Jim Chinitz of Population Diagnostics, Inc., Bill Ponton of US Biomarkers, Inc., and Lawrence A. Horn of MPEG LA, LLC.  Rounding out the panel was Manjula Donepudi, Ph.D., Assistant Director, Office of Technology Transfer, The Rockefeller University.  Dr. Donepudi provided insight from the academic world on how the changes in the patent eligibility laws have impacted the prosecution strategies and licensing of biomarker and molecular diagnostic inventions originating from universities and other academic institutions.  The panel shined light on just one of the many important topics being addressed at the NewYorkBIO annual conference, which marked NewYorkBIO’s 25 years of life science development in New York, from the humble beginnings of a handful of researchers and companies, to the multi-billion dollar enterprise that it is today.  For a quarter century, NewYorkBIO has been the voice of New York’s life science community, helping to define the industry, protect its interests, and grow its opportunities.